Alan Tan, MD, discusses upcoming trials that could change the landscape of frontline and adjuvant renal cell carcinoma ...
Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.
Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...
BMS has reported that the Phase II TRANSCEND FL trial assessing Breyanzi, met its primary endpoint in the marginal zone ...
The FDA has granted fast track designation to amezalpat for the treatment of patients with hepatocellular carcinoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback